ClinicalTrials.gg
WithdrawnNCT05956652Updated Aug 18, 2026

Hydra Registry - Italy Experience

An observational study in Aortic Valve Stenosis, sponsored by Sahajanand Medical Technologies Limited. Withdrawn at 4 sites in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Sahajanand Medical Technologies Limited · Observational

How we know

Why this study was withdrawn
Withdrawn (No Participants Enrolled)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
0
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 118 studies in Aortic Valve Stenosis with a site in Italy — 39 open to participants now, 54 under way, 1 of them phase 3. Aortic Valve Stenosis · Italy.

Enrollment
71st of 71
0 · median 500
Started
2023
with 9 others
Observational
71 of 118
21 open now
Registered
92nd of 118
by date

Among the 118 studies in Aortic Valve Stenosis with a site in Italy, this one is the 71st largest by enrollment of the 71 observational ones that give a count, is one of 10 that started in 2023, is one of 71 observational ones, and was the 92nd registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

39 of the 118 studies in Aortic Valve Stenosis with a site in Italy are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Aortic Valve Stenosis with a site in Italy, or all of them as a file.
02

Study summary

Hydra-IT is a multicenter observational study aim to collect clinical, procedural and follow-up data and evaluate the short, medium and long term results of Hydra TAVI System in patient with severe aortic stenosis.

Read the detailed description

Hydra-IT is a multicenter observational study conducted across different centres in Italy. The primary objective of the study is to evaluate the safety and efficacy of transcatheter aortic valve implantation and clinical outcome in patients treated with Hydra device. Secondary objective is to evaluate the long term (up to 5 years) effectiveness and the quality of treatment using Hydra device. Patients with severe stenosis symptomatic of the native aortic valve or bioprosthesis in a degenerated aortic position will be included in this study.

03

Conditions studied

  • Aortic Valve Stenosis

Keywords

  • Aortic Valve Stenosis
  • TAVI
  • Hydra
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient with severe aortic valve stenosis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with severe symptomatic native aortic valve stenosis and candidates for the TAVI procedure based on the evaluation of the Heart Team
  • Ability to understand and provide for inclusion in the study

Exclusion criteria

Exclusion Criteria:

  • to TAVI: e.g. evidence of intracardiac mass, thrombus or vegetation, endocarditis.
  • Refusal by the patient to participate in the study
  • High probability of non-adherence to required follow-ups
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
0 participants (actual)
Target follow-up
5 Years
Patient registry
Yes

Interventions

  • DeviceHydra Transcatheter Aortic Valve System

    The Hydra device is self-expanding transcatheter aortic valve consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.

06

What researchers measure

Primary outcomes

  1. Cardiovascular mortality

    Time frame: 30 days

Secondary outcomes

  1. All-cause mortality

    Cardiovascular mortality, valve-related mortality, and non-cardiovascular mortality

    Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years

  2. All stroke

    Disabling and non-disabling stroke

    Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years

  3. Disabling stroke

    Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years

  4. Myocardial infarction

    Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years

  5. Life-threatening or disabling bleeding

    Time frame: 30 days

  6. Major vascular complications

    Time frame: 30 days

  7. Acute kidney injury (Stage 2 or 3)

    Time frame: 30 days

  8. New permanent pacemaker implantation (PPM)

    Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years

  9. Paravalvular Leak (PVL)

    Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years

  10. Effective Orifice Area (EOA)

    Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years

  11. Mean aortic valve gradient

    Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years

  12. New York Heart Association (NYHA) functional classification

    Time frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years

07

Study locations

4 sites
  • Fondazione Poliambulanza Istituto
    Brescia, 25124, Italy
  • Montevergine Clinic, Mercogliano, Italy
    Mercogliano, 83013, Italy
  • IRCCS Ospedale Galeazzi-Sant'Ambrogio
    Milan, 20157, Italy
  • Università degli studi di Padova
    Padova, 35122, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Jul 2027, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2023
First posted
Jul 21, 2023
StartActual
Jul 1, 2023
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2029
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05956652
Lead sponsor
Sahajanand Medical Technologies Limited
Collaborators
Clinica Di Montevergine
Responsible party
Sponsor
First posted
Jul 21, 2023
Start date
Jul 1, 2023
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Aug 18, 2026

Study contacts

Dr. Angelo Cioppa
principal investigator · Montevergine Clinic, Mercogliano, Italy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion